{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:49:04Z","timestamp":1777960144994,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015503","name":"Lieber Institute for Brain Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015503","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The L-type calcium channel gene, CACNA1C, is a validated risk gene for schizophrenia and the target of calcium channel blockers. Carriers of the risk-associated genotype (rs1006737 <jats:italic>A<\/jats:italic> allele) have increased frontal cortical activity during working memory and higher CACNA1C mRNA expression in the prefrontal cortex. The aim of this study was to determine how the brain-penetrant calcium channel blocker, nimodipine, changes brain activity during working memory and other cognitive and emotional processes. We conducted a double-blind randomized cross-over pharmacoMRI study of a single 60\u2009mg dose of oral nimodipine solution and matching placebo in healthy men, prospectively genotyped for rs1006737. With performance unchanged, nimodipine significantly decreased frontal cortical activity by 39.1% and parietal cortical activity by 42.8% during the N-back task (2-back\u2009&gt;\u20090-back contrast; <jats:italic>P<\/jats:italic><jats:sub>FWE<\/jats:sub>\u2009&lt;\u20090.05; <jats:italic>n<\/jats:italic>\u2009=\u200928). Higher peripheral nimodipine concentrations were correlated with a greater decrease in activation in the frontal cortex. Carriers of the risk-associated allele, <jats:italic>A<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u200914), had a greater decrease in frontal cortical activation during working memory compared to non-risk allele carriers. No differences in brain activation were found between nimodipine and placebo for other tasks. Future studies should be conducted to test if the decreased cortical brain activity after nimodipine is associated with improved working memory performance in patients with schizophrenia, particularly those who carry the risk-associated genotype. Furthermore, changes in cortical activity during working memory may be a useful biomarker in future trials of L-type calcium channel blockers.<\/jats:p>","DOI":"10.1038\/s41398-020-01066-z","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T17:03:41Z","timestamp":1604336621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nimodipine improves cortical efficiency during working memory in healthy subjects"],"prefix":"10.1038","volume":"10","author":[{"given":"Caroline F.","family":"Zink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mellissa","family":"Giegerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greer E.","family":"Prettyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla E.","family":"Carta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"van Ginkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly P.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eesha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Breakey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Hummert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay J.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2409-2969","authenticated-orcid":false,"given":"Daniel R.","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-9008","authenticated-orcid":false,"given":"Kristin L.","family":"Bigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"key":"1066_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/archgenpsychiatry.2010.96","volume":"67","author":"KL Bigos","year":"2010","unstructured":"Bigos, K. L. et al. Genetic variation in CACNA1C affects brain circuitries related to mental illness. Arch. Gen. Psychiatry 67, 939\u2013945 (2010).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1066_CR2","doi-asserted-by":"crossref","unstructured":"Green, E. K. et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol. Psychiatry. 15, 1016\u20131022(2009).","DOI":"10.1038\/mp.2009.49"},{"key":"1066_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nature08185","volume":"460","author":"International Schizophrenia Consortium.","year":"2009","unstructured":"International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748\u2013752 (2009).","journal-title":"Nature"},{"key":"1066_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium.","year":"2014","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421\u2013427 (2014).","journal-title":"Nature"},{"key":"1066_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/sj.mp.4002151","volume":"13","author":"P Sklar","year":"2008","unstructured":"Sklar, P. et al. Whole-genome association study of bipolar disorder. Mol. Psychiatry. 13, 558\u2013569 (2008).","journal-title":"Mol. Psychiatry."},{"key":"1066_CR6","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/ng.209","volume":"40","author":"MAR Ferreira","year":"2008","unstructured":"Ferreira, M. A. R. et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet 40, 1056\u20131058 (2008).","journal-title":"Nat. Genet"},{"key":"1066_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1176\/appi.ajp.160.4.709","volume":"160","author":"JH Callicott","year":"2003","unstructured":"Callicott, J. H. et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am. J. Psychiatry 160, 709\u2013719 (2003).","journal-title":"Am. J. Psychiatry"},{"key":"1066_CR8","doi-asserted-by":"publisher","unstructured":"Hayes, J. F., et al. Association of hydroxylmethyl glutaryl coenzyme a reductase inhibitors, l-type calcium channel antagonists, and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness. JAMA Psychiatry. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3907 (2019).","DOI":"10.1001\/jamapsychiatry.2018.3907"},{"key":"1066_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/JCP.0b013e31823f9116","volume":"32","author":"OA De Le\u00f3n","year":"2012","unstructured":"De Le\u00f3n, O. A. Response to nimodipine in ultradian bipolar cycling after amygdalohippocampectomy. J. Clin. Psychopharmacol. 32, 146\u2013148 (2012).","journal-title":"J. Clin. Psychopharmacol."},{"key":"1066_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0022-3956(94)00047-U","volume":"29","author":"J Walden","year":"1995","unstructured":"Walden, J., Fritze, J., Van Calker, D., Berger, M. & Grunze, H. A calcium antagonist for the treatment of depressive episodes: single case reports. J. Psychiatr. Res. 29, 71\u201376 (1995).","journal-title":"J. Psychiatr. Res."},{"key":"1066_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/00004714-199810000-00009","volume":"18","author":"P Pazzaglia","year":"1998","unstructured":"Pazzaglia, P. et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J. Clin. Psychopharmacol. 18, 404\u2013413 (1998).","journal-title":"J. Clin. Psychopharmacol."},{"key":"1066_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0165-1781(93)90066-P","volume":"49","author":"PJ Pazzaglia","year":"1993","unstructured":"Pazzaglia, P. J., Post, R. M., Ketter, T. A., George, M. S. & Marangell, L. B. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res. 49, 257\u2013272 (1993).","journal-title":"Psychiatry Res."},{"key":"1066_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/00002826-199006000-00004","volume":"13","author":"G Brunet","year":"1990","unstructured":"Brunet, G. et al. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin. Neuropharmacol. 13, 224\u2013228 (1990).","journal-title":"Clin. Neuropharmacol."},{"key":"1066_CR14","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1067\/mob.2002.125279","volume":"187","author":"DR Yingling","year":"2002","unstructured":"Yingling, D. R., Utter, G., Vengalil, S. & Mason, B. Calcium channel blocker, nimodipine, for the treatment of bipolar disorder during pregnancy. Am. J. Obstet. Gynecol. 187, 1711\u20131712 (2002).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"1066_CR15","doi-asserted-by":"crossref","unstructured":"van den Kerckhoff, W. & Drewes, L. R. in Diagnosis and Treatment of Senile Dementia (eds Manfred Bergener & Barry Reisberg) 308-321 (Springer Berlin Heidelberg, 1989).","DOI":"10.1007\/978-3-642-46658-8_24"},{"key":"1066_CR16","unstructured":"Nimotop [package insert], https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/018869s014lbl.pdf"},{"key":"1066_CR17","unstructured":"Nymalize [package insert] (Arbor Pharmaceuticals, LLC, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/203340lbl.pdf)"},{"key":"1066_CR18","doi-asserted-by":"crossref","unstructured":"First, M. B., Spitzer, R. L., Gibbon, M. & Williams, J. B. W. Structured Clinical Interview for DSM-IV Axis I Disorders -- Patient Edition (SCID-I\/P, Version 2.0). (Biometrics Research Department, New York State Psychiatric Institute, 1995).","DOI":"10.1037\/t07827-000"},{"key":"1066_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0028-3932(71)90067-4","volume":"9","author":"RC Oldfield","year":"1971","unstructured":"Oldfield, R. C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 9, 97\u2013113 (1971).","journal-title":"Neuropsychologia"},{"key":"1066_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.neuroimage.2018.05.021","volume":"178","author":"A Kohli","year":"2018","unstructured":"Kohli, A. et al. Using expectancy theory to quantitatively dissociate the neural representation of motivation from its influential factors in the human brain: An fMRI study. NeuroImage 178, 552\u2013561 (2018).","journal-title":"NeuroImage"},{"key":"1066_CR21","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.1071829","volume":"297","author":"AR Hariri","year":"2002","unstructured":"Hariri, A. R. et al. Serotonin transporter genetic variation and the response of the human amygdala.[see comment]. Science 297, 400\u2013403 (2002).","journal-title":"Science"},{"key":"1066_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/npp.2012.250","volume":"38","author":"F Sambataro","year":"2013","unstructured":"Sambataro, F. et al. Altered cerebral response during cognitive control: a potential indicator of genetic liability for schizophrenia. Neuropsychopharmacology 38, 846\u2013853 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"1066_CR23","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.dib.2018.01.089","volume":"20","author":"P Lanka","year":"2018","unstructured":"Lanka, P. & Deshpande, G. Resting state fMRI data from subjects scanned with the EPI-PACE (Echoplanar Imaging - Prospective Acquisition CorrEction) sequence. Data brief. 20, 2072\u20132075 (2018).","journal-title":"Data brief."},{"key":"1066_CR24","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.neuroimage.2012.01.129","volume":"60","author":"MM Plichta","year":"2012","unstructured":"Plichta, M. M. et al. Test\u2013retest reliability of evoked BOLD signals from a cognitive\u2013emotive fMRI test battery. NeuroImage 60, 1746\u20131758 (2012).","journal-title":"NeuroImage"},{"key":"1066_CR25","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s41593-018-0197-y","volume":"21","author":"AE Jaffe","year":"2018","unstructured":"Jaffe, A. E. et al. Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nat. Neurosci. 21, 1117\u20131125 (2018).","journal-title":"Nat. Neurosci."},{"key":"1066_CR26","first-page":"445","volume":"9","author":"G Vaseghi","year":"2014","unstructured":"Vaseghi, G., Hajhashemi, V. & Rabbani, M. The effect of nimodipine on memory loss following naloxone-induced morphine withdrawal in object recognition. Res. Pharm. Sci. 9, 445\u2013451 (2014).","journal-title":"Res. Pharm. Sci."},{"key":"1066_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep13633","volume":"5","author":"AP Crestani","year":"2015","unstructured":"Crestani, A. P. et al. Memory reconsolidation may be disrupted by a distractor stimulus presented during reactivation. Sci. Rep. 5, 13633 (2015).","journal-title":"Sci. Rep."},{"key":"1066_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-015-0262-3","volume":"12","author":"SC Hopp","year":"2015","unstructured":"Hopp, S. C. et al. Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation. J. Neuroinflamm. 12, 1\u201314 (2015).","journal-title":"J. Neuroinflamm."},{"key":"1066_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2013.04.005","volume":"244","author":"L De Oliveira Alvares","year":"2013","unstructured":"De Oliveira Alvares, L. et al. Reactivation enables memory updating, precision-keeping and strengthening: exploring the possible biological roles of reconsolidation. Neuroscience 244, 42\u201348 (2013).","journal-title":"Neuroscience"},{"key":"1066_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1749-6632.1994.tb44421.x","volume":"747","author":"RJ Fanelli","year":"1994","unstructured":"Fanelli, R. J., McCarthy, R. T. & Chisholm, J. Neuropharmacology of Nimodipine: From Single Channels to Behavior. Ann. N. Y. Acad. Sci. 747, 336\u2013350 (1994).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1066_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0197-4580(92)90010-U","volume":"13","author":"TE Levere","year":"1992","unstructured":"Levere, T. E. & Walker, A. Old age and cognition: enhancement of recent memory in aged rats by the calcium channel blocker nimodipine. Neurobiol. Aging 13, 63\u201366 (1992).","journal-title":"Neurobiol. Aging"},{"key":"1066_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/0091-3057(91)90164-W","volume":"39","author":"A Levy","year":"1991","unstructured":"Levy, A. et al. Nimodipine improves spatial working memory and elevates hippocampal acetylcholine in young rats. Pharmacol. Biochem. Behav. 39, 781\u2013786 (1991).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1066_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0014-2999(98)00250-7","volume":"350","author":"A Batuecas","year":"1998","unstructured":"Batuecas, A. et al. Effects of chronic nimodipine on working memory of old rats in relation to defects in synaptosomal calcium homeostasis. Eur. J. Pharmacol. 350, 141\u2013150 (1998).","journal-title":"Eur. J. Pharmacol."},{"key":"1066_CR34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0091-3057(93)90013-J","volume":"44","author":"K McMonagle-Strucko","year":"1993","unstructured":"McMonagle-Strucko, K. & Fanelli, R. J. Enhanced acquisition of reversal training in a spatial learning task in rats treated with chronic nimodipine. Pharmacol. Biochem. Behav. 44, 827\u2013835 (1993).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"1066_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neuroscience.2014.09.007","volume":"280","author":"SC Hopp","year":"2014","unstructured":"Hopp, S. C. et al. Differential rescue of spatial memory deficits in aged rats by L-type voltage-dependent calcium channel and ryanodine receptor antagonism. Neuroscience 280, 10\u201318 (2014).","journal-title":"Neuroscience"},{"key":"1066_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0197-4580(90)90120-O","volume":"11","author":"M Sandin","year":"1990","unstructured":"Sandin, M., Jasmin, S. & Levere, T. E. Aging and cognition: Facilitation of recent memory in aged nonhuman primates by nimodipine. Neurobiol. Aging 11, 573\u2013575 (1990).","journal-title":"Neurobiol. Aging"},{"key":"1066_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-pharmtox-010715-103617","volume":"56","author":"AFT Arnsten","year":"2016","unstructured":"Arnsten, A. F. T. & Wang, M. Targeting prefrontal cortical systems for drug development: potential therapies for cognitive disorders. Annu Rev. Pharm. Toxicol. 56, 339\u2013360 (2016).","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"1066_CR38","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1021\/acschemneuro.7b00505","volume":"9","author":"D Datta","year":"2018","unstructured":"Datta, D. & Arnsten, A. F. T. Unique molecular regulation of higher-order prefrontal cortical circuits: insights into the neurobiology of schizophrenia. ACS Chem. Neurosci. 9, 2127\u20132145 (2018).","journal-title":"ACS Chem. Neurosci."},{"key":"1066_CR39","first-page":"274","volume":"45","author":"W Wang","year":"2006","unstructured":"Wang, W., Wang, L. N., Zhang, X. H., Ma, L. & Li, D. J. A nimodipine interventional study of patients with mild cognitive impairment. Zhonghua Nei Ke Za Zhi 45, 274\u2013276 (2006).","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"1066_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0278-5846(90)90005-2","volume":"14","author":"TA Ban","year":"1990","unstructured":"Ban, T. A. et al. Nimodipine in the treatment of old age dementias. Prog. Neuro Psychopharmacol. Biol. Psychiatry 14, 525\u2013551 (1990).","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"1066_CR41","doi-asserted-by":"publisher","unstructured":"Tollefson, G. D. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol. Psychiatry. https:\/\/doi.org\/10.1016\/0006-3223(90)90050-C (1990).","DOI":"10.1016\/0006-3223(90)90050-C"},{"key":"1066_CR42","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/01.STR.0000155686.73908.3e","volume":"36","author":"L Pantoni","year":"2005","unstructured":"Pantoni, L. et al. Efficacy and safety of nimodipine in subcortical vascular dementia. Stroke 36, 619 (2005).","journal-title":"Stroke"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-01066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-01066-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-01066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:59:15Z","timestamp":1670252355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-020-01066-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1038\/s41398-020-01066-z","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"9 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"372"}}